DelveInsight’s, “TRAIL Receptor 2 Agonists - Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in TRAIL Receptor 2 Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
TRAIL Receptor 2 Agonists: Overview
TRAIL receptor 2 (TRAILR2), also known as Death receptor 5 (DR5), is a cell surface receptor of the TNF-receptor superfamily that binds TRAIL and mediates apoptosis. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) preferentially induces apoptosis in neoplastic cells upon binding to its receptors TRAIL-R1 and TRAIL-R2. This biological principle has been adopted for the development of cancer-selective therapies. However, many tumor cells are resistant to TRAIL and moreover TRAIL-R1/R2 can activate pro-inflammatory pathways thereby promoting invasion, migration, and metastasis
The companies and academics are working to assess challenges and seek opportunities that could influence TRAIL Receptor 2 Agonists R&D. The therapies under development are focused on novel approaches for TRAIL Receptor 2 Agonists.
This segment of the TRAIL Receptor 2 Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TRAIL Receptor 2 Agonists Emerging Drugs
INBRX-109: Inhibrx
INBRX-109 is a tetravalent DR5 agonistic antibody, is designed to exploit tumor-biased direct cell death induction by DR5 activation in numerous cancer types. With a valency of four, it has the ability to potently agonize DR5 through efficient receptor clustering, causing cell death, but by way of our sdAb platform, also eliminates recognition by pre-existing anti-drug antibodies (ADAs) to lessen the potential for hyper-clustering. In January 2021, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma.
BI 905711: Travere Therapeutics
BI 905711 is a tetravalent bispecific antibody that cross-links the pro-apoptotic tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor 2 (TRAILR2) with the tumor cell anchor cadherin 17 (CDH17). CDH17-dependent clustering of TRAILR2 allows BI 905711 to induce selective apoptosis in CDH17-expressing tumor cells. BI 905711 is currently being investigated in patients with advanced gastrointestinal (GI) cancers.
Further product details are provided in the report……..
This segment of the report provides insights about the different TRAIL Receptor 2 Agonists drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the TRAIL Receptor 2 Agonists. The companies which have their TRAIL Receptor 2 Agonists drug candidates in the most advanced stage, i.e. Phase II include, Inhibrx.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
TRAIL Receptor 2 Agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TRAIL Receptor 2 Agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TRAIL Receptor 2 Agonists drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
TRAIL Receptor 2 Agonists: Overview
Pipeline Therapeutics
Therapeutic Assessment
TRAIL Receptor 2 Agonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
INBRX-109: Inhibrx
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
BI 905711: Boehringer Ingelheim
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
TLY 012: Theraly Fibrosis
Drug profiles in the detailed report…..
Inactive Products
TRAIL Receptor 2 Agonists Key Companies
TRAIL Receptor 2 Agonists Key Products
TRAIL Receptor 2 Agonists- Unmet Needs
TRAIL Receptor 2 Agonists- Market Drivers and Barriers
TRAIL Receptor 2 Agonists- Future Perspectives and Conclusion
TRAIL Receptor 2 Agonists Analyst Views
TRAIL Receptor 2 Agonists Key Companies
Appendix
List of Table
Table 1: Total Products for TRAIL Receptor 2 Agonists
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for TRAIL Receptor 2 Agonists
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Inhibrx
• Boehringer Ingelheim
• IGM Biosciences
• Amgen
• Genmab
• Theraly Fibrosis
• IGM Biosciences
